The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer

European Journal of Medical Research

Volumn 18, Issue 1, 2013, Pages

  Yu, Shengqiang ^a   Feng, Fan ^a   Wang, Ke ^a   Men, Changping ^a   Lin, Chunhua ^a   Liu, Qingzuo ^a   Yang, Diandong ^a   Gao, Zhenli ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Cell apoptosis; Monoclonal antibody; Prostate cancer; Prostate stem cell antigen; Radioimmunotherapy

Indexed keywords

IMMUNOGLOBULIN G; IODINE 131; MONOCLONAL ANTIBODY; PROSTATE STEM CELL ANTIGEN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; PSCA PROTEIN, HUMAN; RADIOACTIVE IODINE; TUMOR ANTIGEN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROL; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; METHYL THIAZOLYL TETRAZOLIUM ASSAY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PROSTATE CANCER; ANIMAL; DISEASE MODEL; IMMUNOLOGY; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR INVASION; PROSTATIC NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; APOPTOSIS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GPI-LINKED PROTEINS; HUMANS; IODINE RADIOISOTOPES; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 84889972633     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-18-56     Document Type: Article

References (27)

1. Cancer statistics, 2010. Jemal A, Siegel R, Xu J, Ward E, CA Cancer J Clin 2010 60 277 300 10.3322/caac.20073 20610543
2. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F, Ann Oncol 2010 21 1323 1360 10.1093/annonc/mdp530 19948741
3. Integrative genomic profiling of human prostate cancer. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Cancer Cell 2010 18 11 22 10.1016/j.ccr.2010.05.026 20579941
4. Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer. Calcagno F, Nguyen T, Dobi E, Villanueva C, Curtit E, Kim S, Montcuquet P, Kleinclauss F, Pivot X, Thiery-Vuillemin A, Clin Med Insights Oncol 2013 7 1 12 23362372
5. Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Huggins CHC, Cancer Res 1941 1 293 297
6. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. Huggins C, Hodges CV, J Urol 2002 167 948 951 discussion 952 10.1016/S0022-5347(02)80307-X 11905923
7. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Hamberg P, Verhagen PC, De Wit R, Eur J Cancer 2008 44 1193 1197 10.1016/j.ejca.2008.04.005 18448326
8. Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Sternberg CN, Ann Oncol 2008 19 Suppl 7 &22ii91 vii95 18790987
9. PSA response to lenalidomide therapy in a pre-treated patient with metastatic prostate cancer refractory to hormones and chemotherapy: a case report. Gasent Blesa JM, Godoy MP, Esparcia MF, Molla SB, Magan BM, Sempere Ortells JM, Sanchez JL, Case Rep Oncol 2012 5 181 186 10.1159/000336481 22666210
10. Variables in predicting survival based on treating "PSA-only" relapse. Moul JW, Urol Oncol 2003 21 292 304 10.1016/S1078-1439(03)00103-0 12954500 (Pubitemid 38542734)
11. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ, J Clin Oncol 2003 21 1232 1237 10.1200/JCO.2003.06.100 12663709 (Pubitemid 46606398)
12. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, et al. Proc Natl Acad Sci U S A 1998 95 1735 1740 10.1073/pnas.95.4.1735 9465086 (Pubitemid 28103463)
13. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE, Oncogene 2000 19 1288 1296 10.1038/sj.onc.1203426 10713670 (Pubitemid 30160621)
14. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE, J Urol 2004 171 1117 1121 10.1097/01.ju.0000109982.60619.93 14767283 (Pubitemid 38327539)
15. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE, Clin Cancer Res 2005 11 2591 2596 10.1158/1078-0432.CCR- 04-1842 15814638 (Pubitemid 40569458)
16. Prostate stem cell antigen: a Jekyll and Hyde molecule? Saeki N, Gu J, Yoshida T, Wu X, Clin Cancer Res 2010 16 3533 3538 10.1158/1078-0432.CCR-09-3169 20501618
17. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC, Mol Ther 2009 17 1101 1108 10.1038/mt.2009.66 19337234
18. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A, Proc Natl Acad Sci U S A 2001 98 2658 2663 10.1073/pnas.051624698 11226295 (Pubitemid 32209538)
19. An interactive medical image segmentation system based on the optimal management of regions of interest using topological medical knowledge. Fasquel JB, Agnus V, Moreau J, Soler L, Marescaux J, Comput Meth Programs Biomed 2006 82 216 230 10.1016/j.cmpb.2006.04.004 (Pubitemid 43850052)
20. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ, Semin Oncol 2003 30 667 676 10.1016/S0093-7754(03)00358-0 14571414 (Pubitemid 37296791)
21. Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Raff AB, Gray A, Kast WM, Cancer Lett 2009 277 126 132 10.1016/j.canlet.2008.08.034 18838214
22. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. Sharkey RM, Goldenberg DM, CA Cancer J Clin 2006 56 226 243 10.3322/canjclin.56.4.226 16870998 (Pubitemid 44175051)
23. Tumor-associated antigens for specific immunotherapy of prostate cancer. Kiessling A, Wehner R, Füssel S, Bachmann M, Wirth MP, Schmitz M, Cancers 2012 4 193 217 10.3390/cancers4010193 24213236
24. Radioimmunotherapy with alpha-particle emitting radionuclides. Zalutsky MR, Pozzi OR, Q J Nucl Med Mol Imaging 2004 48 289 296 15640792
25. A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, et al. Clin Cancer Res 2003 9 5842 5852 14676105 (Pubitemid 38018066)
26. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Dadachova E, Nosanchuk JD, Shi L, Schweitzer AD, Frenkel A, Nosanchuk JS, Casadevall A, Proc Natl Acad Sci U S A 2004 101 14865 14870 10.1073/pnas.0406180101 15469923 (Pubitemid 39410766)
27. Chamarthy M.R.Williams S.C.Moadel R.M., Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets', Yale J Biol Med, 2011, 84, 391-407, 22180677.